<DOC>
	<DOCNO>NCT01157104</DOCNO>
	<brief_summary>This study design evaluate potential pharmacokinetic ( PK ) drug-drug interaction IDX320 IDX184 ass safety tolerability two drug administer combination healthy participant .</brief_summary>
	<brief_title>A Drug-Drug Interaction Study Evaluating Combination IDX320 IDX184 Healthy Participants ( MK-6844-002 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>To participate study , participant must meet following requirement : 1 . Must healthy male female 19 65 year age body mass index ( BMI ) 18 35 kg/m2 . 2 . Must nonsmoker . 3 . Must agree use acceptable doublebarrier method birth control . 4 . Must provide write informed consent study fully explain . Participants eligible meet following : 1 . Pregnant breastfeeding . 2 . History clinically significant disease , determine investigator . 3 . Safety laboratory abnormality screen clinically significant . 4 . Positive screen test hepatitis B virus , hepatitis C virus human immunodeficiency virus ( HIV ) . 5 . Use chronic prescription medication within 3 month , acute prescription medication within 14 day , systemic overthecounter ( OTC ) medication within 7 day start study . 6 . Current abuse alcohol illicit drug , history alcohol illicit drug abuse within precede two year .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>HCV</keyword>
	<keyword>Hepatitis C</keyword>
</DOC>